Treatment Guidelines for Psoriasis

First-Line Topical Therapy

For mild to moderate plaque psoriasis, combination calcipotriene/betamethasone dipropionate ointment applied once daily is the most effective first-line topical treatment, with strength of recommendation A and level I evidence. 1

Topical Corticosteroids

High-potency topical corticosteroids (Class I-II) such as clobetasol 0.05% or fluocinonide 0.05% are highly effective for trunk and extremity lesions, with greater efficacy than less potent agents. 1
Maximum weekly use of clobetasol and halobetasol should not exceed 50 grams. 1
Treatment duration with Class I steroids should be limited to 2-4 weeks, followed by gradual reduction in usage; unsupervised continuous use is not recommended. 1
For facial and genital psoriasis, avoid high-potency steroids entirely; instead use low-potency agents (Class V-VII) or preferably topical calcineurin inhibitors. 1

Vitamin D Analogues

Calcipotriene (calcipotriol) monotherapy is recommended with strength A, level I evidence, working by inhibiting keratinocyte proliferation and enhancing differentiation. 1
The combination of calcipotriene with betamethasone dipropionate is more effective than either agent alone (strength A, level I evidence). 1
When using calcipotriene on large body surface areas, monitor vitamin D metabolites and calcium levels to prevent hypercalcemia. 1

Phototherapy

Narrowband UVB (NB-UVB) phototherapy is safe, effective, and cost-effective for moderate to severe psoriasis, requiring 20-25 treatments given 2-3 times weekly for significant improvement. 1, 2

NB-UVB is more effective than broadband UVB and can be administered in-office or at home to reduce travel burden. 1
PUVA (psoralen plus UVA) therapy is very effective with potential for long remissions, but long-term use in Caucasians increases risk of squamous cell carcinoma and possibly melanoma. 1
PUVA is contraindicated in pregnancy due to oral psoralen. 1
NB-UVB is preferred over PUVA because it avoids photoaging, lentigines, and nausea while being only slightly less effective. 1

Systemic Agents

Methotrexate

Methotrexate is effective in the majority of patients but requires careful monitoring for hepatotoxicity. 1
Contraindications include: pregnancy, renal impairment, hepatitis, cirrhosis, alcoholism, unreliable patients, leukemia, and thrombocytopenia. 1
Drug interactions are common, with bone marrow suppression a major concern. 1
Prior guidelines suggest liver biopsy after 1.5-gram cumulative dose. 1
Methotrexate is teratogenic and requires a mandatory 3-month washout before conception attempts. 3

Cyclosporine

Cyclosporine works rapidly and is effective in the majority of patients, but is best used interventionally in short-term courses of 3-4 months. 1
Adverse effects include: impaired renal function, hypertension, concerns about lymphoma, and potential increase in cutaneous malignancies with long-term use. 1
Numerous drug interactions exist. 1

Acitretin

Acitretin is absolutely contraindicated in women of childbearing potential due to teratogenicity that persists for up to 3 years after discontinuation when reverse-esterified to etretinate in the presence of alcohol. 1, 3
Dosing is typically 0.1-1 mg/kg/day for pediatric patients. 1
Concomitant treatment with NB-UVB is synergistic and often allows for dose reduction. 1

Apremilast

Apremilast is an oral phosphodiesterase 4 inhibitor approved for moderate to severe plaque psoriasis. 2
It can be considered for moderate to severe ICI-related psoriasis. 1

Biologic Therapy

The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because of their efficacy and acceptable safety profiles. 2

TNF-α Inhibitors

Etanercept, adalimumab, certolizumab, and infliximab inhibit tumor necrosis factor α. 2
These agents are also approved for psoriatic arthritis. 2
TNF-α inhibitors are considered the safest systemic option for women of childbearing age among available systemic therapies. 3

IL-12/23 Inhibitors

Ustekinumab inhibits the p40 subunit of IL-12 and IL-23, with weight-based dosing and a good safety profile. 3, 2
It is also approved for psoriatic arthritis. 2

IL-17 Inhibitors

Secukinumab, ixekizumab, bimekizumab, and brodalumab inhibit IL-17. 2
Secukinumab has shown no adverse developmental effects in animal studies, though limited human pregnancy data exists. 3
These agents are also approved for psoriatic arthritis. 2

IL-23 Inhibitors

Guselkumab, tildrakizumab, risankizumab, and mirikizumab inhibit the p19 subunit of IL-23. 2

Special Considerations: Pregnancy

For women of childbearing potential with severe psoriasis, narrowband UVB phototherapy is the first-line treatment given its high efficacy and lack of teratogenic risks. 3

Safe Options

NB-UVB phototherapy 2-3 times weekly is the preferred treatment, often combined with topical calcipotriene/betamethasone dipropionate. 3
Biologics (TNF-α inhibitors, secukinumab, ustekinumab) are considered second-line systemic options with favorable safety profiles. 3
Topical corticosteroids and vitamin D analogues can work safely and effectively. 4

Contraindicated Therapies

Acitretin is absolutely contraindicated due to 3-year teratogenicity risk. 1, 3
Tazarotene should be avoided due to teratogenic potential. 1, 3
Methotrexate requires 3-month washout before conception. 3
Oral psoralen (PUVA) is contraindicated. 1

Critical Counseling

Discuss contraception and pregnancy planning before initiating any systemic therapy, ensuring reliable contraception. 3

Special Considerations: Pediatric Patients

Topical Therapy (Ages 12 and Older)

Calcipotriol/betamethasone dipropionate ointment once daily for up to 4 weeks is recommended (strength B) for children ≥12 years with mild to moderate plaque psoriasis. 1
For scalp psoriasis, calcipotriol/betamethasone dipropionate suspension once daily for up to 8 weeks is recommended (strength B) for children ≥12 years. 1
58% of pediatric patients (12-17 years) achieved scalp disease clearance after 8 weeks. 1

Sensitive Areas in Children

Tacrolimus 0.1% ointment is recommended for facial and genital psoriasis (strength C) in pediatric patients. 1, 5
88% of children with facial or inverse psoriasis achieved clearance or excellent improvement within 30 days. 5
Complete clearance of facial psoriasis was achieved within 72 hours in case series. 5

Steroid-Sparing Strategies

Rotational therapy with topical vitamin D analogues, calcineurin inhibitors, emollients, tar-based therapies, and topical corticosteroids is recommended to reduce steroid exposure (strength C). 1, 5
A common approach involves applying topical corticosteroids on weekends and calcitriol on weekdays after initial combination therapy. 1

Infants and Young Children (0-6 Years)

Infants and children 0-6 years are uniquely vulnerable to HPA axis suppression due to high body surface area-to-volume ratio. 1, 5
Use only low-potency corticosteroids (hydrocortisone 1-2.5%) in this age group. 5
High-potency or ultra-high-potency topical corticosteroids should be avoided entirely in infants and young children. 5
Prescribe limited quantities with explicit instructions on amount and application sites. 1, 5
Assess growth parameters in children requiring long-term topical corticosteroid therapy. 1, 5

Monitoring in Pediatric Patients

Monitor vitamin D metabolites when calcipotriene is applied to large body surface areas (strength B). 1
Maximum recommended dosages to prevent hypercalcemia: 50 g/week/m² for calcipotriol and 100 g/week/m² for calcipotriene. 1
At any age, vitamin D analogues should be used with caution in patients with calcium metabolism disorders or kidney disease. 1

Systemic Therapy in Pediatric Patients

Biologics

Etanercept is recommended for moderate to severe psoriasis in children ≥6 years (strength A), dosed subcutaneously at 0.8 mg/kg (maximum 50 mg) once weekly. 1
Adalimumab is recommended for off-label use (strength B) at 0.8 mg/kg (maximum 40 mg) at weeks 0 and 1, then every other week. 1
Ustekinumab is recommended for adolescents ≥12 years (strength A) with weight-based dosing: 0.75 mg/kg if <60 kg, 45 mg if 60-≤100 kg, 90 mg if >100 kg. 1
Infliximab can be recommended for severe, rapidly progressive, or life-threatening disease (strength C) at 5 mg/kg on weeks 0,2,6, then every 8 weeks. 1
The major risk is injection site reaction, but monitor for increased infection risk (strength B). 1

Other Systemic Agents

Methotrexate is the most common systemic medication used for moderate to severe pediatric psoriasis. 5
Acitretin should be avoided or used with extreme caution in adolescent females due to teratogenicity risk. 1

Common Pitfalls in Pediatric Psoriasis

Abrupt discontinuation of high-potency corticosteroids causes rebound flares; taper gradually. 1, 5
Do not combine salicylic acid with calcipotriene concurrently; acidic pH inactivates calcipotriene. 1, 5
Regular dermatology follow-up is essential to ensure proper technique and prevent overuse. 5

Treatment Algorithm for Moderate to Severe Psoriasis

For limited disease (<10% BSA): Start with topical calcipotriene/betamethasone dipropionate or high-potency corticosteroids. 1
For extensive disease or inadequate topical response: Initiate NB-UVB phototherapy 2-3 times weekly. 1, 3
If phototherapy fails or is impractical: Consider systemic therapy or biologics. 1
For patients with psoriatic arthritis: Anti-TNF biologics or methotrexate are preferred. 1
For women of childbearing potential: NB-UVB first-line, then biologics if needed; avoid acitretin, tazarotene, and methotrexate without adequate washout. 3
For rapidly progressive or life-threatening disease: Short-term cyclosporine (3-4 months) can bridge to biologic therapy. 3

What are the current treatment guidelines for psoriasis, including first‑line topical therapy, phototherapy, systemic agents, biologics, and special considerations such as pregnancy and pediatric patients?

Help us tailor your experience